-transparent.png){kind=logo}
BACKGROUND The recognized role of angiotensin II (Ang II) in the pathogenesis of the progression of renal disease cannot be solely attributed to Ang II's hemodynamic effects. Indeed, growth stimulating signals driven by Ang II promote mesangial cell (MC) hypertrophy and extracellular matrix production, prominent features of progressive glomerular injury. Superoxide anion (O2-) avidly interacts with nitric oxide, an endogenous vasodilator that inhibits growth factor stimulated MC growth and matrix production. In addition, O2- acting as an intracellular signal is linked to growth related responses such as activation of mitogen activated protein (MAP) kinases. The studies reported herein were designed to investigate: (a) whether Ang II induces MC O2-production and (b) if increased O2- production elicits growth responses in MC. METHODS MC were exposed to Ang II for 24 or 48 hours. In some experiments, in addition to Ang II, MC were exposed to: diphenylenieodonium (DPI), an inhibitor of the flavin containing NADH/NADPH oxidase; losartan (LOS), an Ang II type 1 (AT1) receptor blocker; PD 98059, a MAP kinases inhibitor; the protein kinase C inhibitors Calphostin C or H-7; and the tyrosine kinase inhibitors, herbymycin A or genistein. RESULTS Ang II (10(-5) M to 10(-8) M) dose dependently increased MC O2- production up to 125% above control (ED 50 5 x 10(-7) M). LOS as well as DPI, and the PKC inhibitors blocked Ang II stimulated MC O2- production. Ang II dose dependently increased MC 3H-leucine incorporation, and MC protein content, two markers of MC hypertrophy, as well as 3H-thymidine incorporation, a marker of MC hyperplasia. PD98059, a specific inhibitor of MAP kinases prevented Ang II induced MC hypertrophy. Moreover, LOS, DPI, and the PKC inhibitors each independently inhibited MC 3H-leucine incorporation, thereby establishing the specificity of Ang II induced O2- in driving MC hypertrophy. CONCLUSIONS The current studies demonstrate a previously unrecognized link between Ang II and MC O2- production that may participate in the pathophysiology of progressive renal disease by concomitantly affecting the hemodynamics of the glomerular microcirculation as well as growth related responses of MC to injury.
E A Jaimes, and
J M Galceran, and
L Raij
November 2003,
American journal of physiology. Renal physiology,
E A Jaimes, and
J M Galceran, and
L Raij
July 1997,
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
E A Jaimes, and
J M Galceran, and
L Raij
July 2006,
Nihon rinsho. Japanese journal of clinical medicine,
E A Jaimes, and
J M Galceran, and
L Raij
January 1995,
Experimental nephrology,
E A Jaimes, and
J M Galceran, and
L Raij
January 2004,
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology,
E A Jaimes, and
J M Galceran, and
L Raij
May 2009,
Pediatric nephrology (Berlin, Germany),
E A Jaimes, and
J M Galceran, and
L Raij
January 2005,
Nephron. Experimental nephrology,
E A Jaimes, and
J M Galceran, and
L Raij
December 2013,
International journal of oncology,
E A Jaimes, and
J M Galceran, and
L Raij
January 1997,
Nephron,
E A Jaimes, and
J M Galceran, and
L Raij
October 1988,
The Journal of surgical research,
